Mithra Pharmaceuticals S.A.
A biotech company developing drugs for contraception, fertility, and menopause.
MITRA | BR
Overview
Corporate Details
- ISIN(s):
- BE0974283153 (+1 more)
- LEI:
- 5493002FDD273HTEKK14
- Country:
- Belgium
- Address:
- Rue Saint-Georges 5, 4000 Liège
- Website:
- https://www.mithra.com/
- Sector:
- Manufacturing
Description
Mithra Pharmaceuticals S.A. is a biotech company dedicated to women's health. The company focuses on the development, manufacturing, and commercialization of differentiated drugs and complex therapeutic solutions. Its core areas of expertise include contraception, fertility, and menopause. Mithra aims to transform the women's health sector by providing innovative choices to support and improve the overall quality of life for women.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-11-10 17:45 |
2021-11-10-Denominator change-FR.pdf
|
French | 174.5 KB | ||
| 2021-10-06 17:45 |
Mithra Provides FDA Update on Myring®
|
English | 159.1 KB | ||
| 2021-10-06 17:45 |
Mithra annonce un update de la FDA concernant Myring®
|
French | 174.3 KB | ||
| 2021-09-24 07:30 |
2021-09-25-First half 2021 financial report EN.pdf
|
English | 695.0 KB | ||
| 2021-09-24 07:30 |
2021-09-24-First half 2021 financial report FR.pdf
|
French | 800.4 KB | ||
| 2021-09-21 17:50 |
Mithra Announces an Update on PeriNesta®
|
English | 148.3 KB | ||
| 2021-09-21 17:50 |
Mithra annonce un update sur PeriNesta®
|
French | 151.8 KB | ||
| 2021-09-21 17:45 |
Donesta® Phase III: Recruitment Completion of American Study and Additional Rec…
|
English | 180.4 KB | ||
| 2021-09-21 17:45 |
Phase III Donesta® : Clôture du recrutement pour l’étude nord-américaine et rec…
|
French | 185.0 KB | ||
| 2021-05-27 07:30 |
NEXTSTELLIS® RECEIVES FDA MARKETING EXCLUSIVITY AND PHASE III DATA PUBLISHED
|
English | 206.7 KB | ||
| 2021-05-27 07:30 |
NEXTSTELLIS® REÇOIT L’EXCLUSIVITÉ COMMERCIALE DE LA FDA ET VOIT SES DONNEES DE …
|
French | 211.5 KB | ||
| 2021-05-20 18:45 |
Mithra Announces European Approval of Estelle®
|
English | 154.8 KB | ||
| 2021-05-20 18:45 |
Mithra annonce l’approbation d’Estelle® en Europe
|
French | 165.3 KB | ||
| 2021-05-20 17:45 |
2021-05-20-New Board of Directors-EN.pdf
|
English | 162.9 KB | ||
| 2021-05-20 17:45 |
2021-05-20-New board of Directors-FR.pdf
|
French | 185.9 KB |
Automate Your Workflow. Get a real-time feed of all Mithra Pharmaceuticals S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mithra Pharmaceuticals S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mithra Pharmaceuticals S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-01-17 | NOSHAQ SA | Board | Other | 172,574 | 617,814.92 EUR |
| 2022-11-17 | NOSHAQ SA | Board | Other | 172,574 | 1,052,701.40 EUR |
| 2022-07-18 | NOSHAQ SA | Board | Other | 156,250 | 1,006,250.00 EUR |
| 2022-05-13 | NOSHAQ SA | Board | Other | 156,250 | 1,239,062.50 EUR |
| 2022-04-13 | Gordenne Valérie | Other | Sell | 8,500 | 87,380.00 EUR |
| 2022-03-29 | Fornieri Francesco | Board | Sell | 100,000 | 1,312,000.00 EUR |
| 2022-03-25 | Fornieri Francesco | Board | Sell | 35,893 | 486,530.57 EUR |
| 2022-03-24 | Fornieri Francesco | Board | Sell | 15,657 | 219,536.19 EUR |
| 2022-03-24 | Fornieri Francesco | Board | Sell | 2,818 | 39,452.00 EUR |
| 2022-03-23 | Fornieri Francesco | Board | Sell | 12,525 | 178,230.75 EUR |
Peer Companies
